{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:25:28Z","timestamp":1777411528514,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:09:18Z","timestamp":1752937758000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Patterns of Patients With Multiple Myeloma in a Real-World Setting in Spain. How are Triple-Class Exposed Patients Being Managed?"],"prefix":"10.1016","volume":"26","author":[{"given":"Julia","family":"Llinares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"Toribio-Castell\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Heredero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-6540","authenticated-orcid":false,"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Ricote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.07.008_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PPO.0000000000000355","article-title":"Novel agents in multiple myeloma","volume":"25","author":"Szalat","year":"2019","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2025.07.008_bib0002","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2023-0021","article-title":"Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe","volume":"19","author":"Mart\u00ednez-Lopez","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0003","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: Can J Clin"},{"issue":"5","key":"10.1016\/j.clml.2025.07.008_bib0004","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2025.07.008_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.17888","article-title":"Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period","volume":"196","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2025.07.008_bib0006","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/life13091841","article-title":"Clinical outcomes of patients with multiple myeloma after Daratumumab failure","volume":"13","author":"Zamanillo","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.clml.2025.07.008_bib0007","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0008","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0009","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.07.008_bib0011","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-022-00757-8","article-title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","volume":"12","author":"Goldman-Mazur","year":"2022","journal-title":"Blood Can J"},{"issue":"34","key":"10.1016\/j.clml.2025.07.008_bib0012","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.2217\/fon-2022-0846","article-title":"Practice patterns and outcomes for triple-class exposed patients with relapsed\/refractory multiple myeloma in Japan","volume":"18","author":"Iida","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0013","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1200\/JCO.2023.41.16_suppl.6618","article-title":"An indirect comparison of elranatamab\u2019s (ELRA) objective response rate (ORR) from MagnetisMM-3 (MM-3) vs real-world external control arms in triple-class refractory (TCR) multiple myeloma (MM)","volume":"41","author":"Costa","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0014","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.07.008_bib0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clinic Proceed"},{"key":"10.1016\/j.clml.2025.07.008_bib0016","unstructured":"National Comprehensive Cancer Network, 2025. NCCN Clinical Practice Guidelines in Oncology; Multiple Myeloma (Version 1.2025)."},{"key":"10.1016\/j.clml.2025.07.008_bib0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0018","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.07.008_bib0019","unstructured":"Grupo de Estudio de Gammapat\u00edas Monoclonales de Castilla y Le\u00f3n. Hematogu\u00eda Mieloma. Versi\u00f3n 5.1:2023."},{"key":"10.1016\/j.clml.2025.07.008_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0021","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0022","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0024","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0025","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.07.008_bib0026","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.07.008_bib0027","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clml.2025.07.008_bib0028","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0029","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S2152-2650(21)02090-5","article-title":"OAB-016: treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019","volume":"21","author":"Perrot","year":"2021","journal-title":"Clin Lymph Myeloma and Leukemia"},{"key":"10.1016\/j.clml.2025.07.008_bib0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clml.2025.07.008_bib0031","first-page":"S217","article-title":"Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials","volume":"23","author":"Weisel","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.07.008_bib0032","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2021.09.013","article-title":"Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study","volume":"43","author":"Dhanasiri","year":"2021","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.clml.2025.07.008_bib0033","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/fon-2022-1018","article-title":"Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma","volume":"19","author":"Hlavacek","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0034","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clml.2023.12.001","article-title":"Characterization and outcomes of Spanish patients with relapsed\/refractory multiple myeloma included in the LocoMMotion study","volume":"24","author":"Mateos","year":"2024","journal-title":"Clin lymph, myeloma & leukemia"},{"key":"10.1016\/j.clml.2025.07.008_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0036","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0037","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0038","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.07.008_bib0039","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of Talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.07.008_bib0040","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"MM-309 CARTITUDE-1 final results: phase 1b\/2 study of Ciltacabtagene Autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.07.008_bib0041","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:53:35Z","timestamp":1768388015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025002538"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns of Patients With Multiple Myeloma in a Real-World Setting in Spain. How are Triple-Class Exposed Patients Being Managed?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}